Nutra Pharma Announces Initial Positive Safety Data from Clinical Study in Adrenomyeloneuropathy (AMN)

BOCA RATON, Fla.--(BUSINESS WIRE)--Aug. 14, 2008 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has reported initial positive safety data from its Phase IIb/IIIa clinical study of RPI-78M for treating Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm's leading drug candidate for treating neurological and autoimmune disorders.

"Initial reports and feedback from physicians involved with this clinical study have reported that patients have experienced no adverse side effects from RPI-78M," explained Paul Reid, CEO of ReceptoPharm. "This is an important indicator of the success of this clinical study, as it provides the medical and pharmacological communities with early evidence supporting the safety of our leading drug candidate, RPI-78M," he concluded.

Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 30,000 people worldwide. The disorder is characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades.

AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS). There is currently no approved treatment for AMN. Additionally, the disease's rarity designates it as an orphan drug candidate both in Europe and in the U.S. The Company has applied for Orphan drug status in the U.S. and intends on doing so for the EU.

ReceptoPharm expects to present the complete clinical findings and data from this study by the end of September.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.ReceptoPharm.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The initial safety data from the clinical study in Adrenomyeloneuropathy (AMN) should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact

Nutra Pharma Corp.
David Isserman, 877-895-5647
IR@nutrapharma.com

Posted: August 2008

View comments

Hide
(web3)